Market reviews 2016

Market review on human pharmaceuticals 2016

Published on 8 February 2017

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in 2016 was up by 4% on the previous year at EUR 2,320 (2,239) million. Orion was able to increase its sales faster than market growth, and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in 2016 amounted to EUR 299 (270) million, up by 11% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 13% (12%).

 

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for slightly over 10% of the Group’s net sales.

 

Total sales of all Parkinson’s drugs:

EUR or USD million

 

MAT9/2016

MAT9/2015

Change %

United States

USD

64

91

-29%

Europe TOP 5

EUR

113

131

-13%

Japan

EUR

76

63

+22%

Source: IMS Health pharmaceutical sales statistics MAT9/2016 (10/2015–9/2016)

Europe TOP 5: Germany, United Kingdom, France, Spain and Italy

 

Total sales of Orion’s branded Parkinson’s drugs:

EUR or USD million

 

MAT9/2016

MAT9/2015

Change %

United States

USD

9

13

-31%

Europe TOP 5

EUR

73

99

-27%

Japan

EUR

76

63

+21%

Source: IMS Health pharmaceutical sales statistics MAT9/2016 (10/2015–9/2016)

*) Sales of generic entacapone products by Sandoz, which is part of the Novartis Group, were previously included in US sales but are no longer included.

Europe TOP 5: Germany, United Kingdom, France, Spain and Italy.

 

Sales of Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan, mainly due to growth in Stalevo, which was launched in that market in 2015.

 

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in September 2016 were up by 2% at EUR 527 (518) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 28% at EUR 44 (34) million in Europe.

 

Published on 25 October 2016

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–September 2016 was up by 4% on the previous year at EUR 1,680 (1,620) million. Orion was able to increase its sales faster than market growth, and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–September 2016 amounted to EUR 217 (195) million, up by 12% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 13% (12%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for under 15% of the Group’s net sales.

Total sales of all Parkinson’s drugs:

EUR or USD million

 

MAT6/2016

MAT6/2015

Change %

United States

USD

876

850

+3%

Europe TOP 5

EUR

919

956

-4%

Japan

EUR

608

543

+12%

Source: IMS Health pharmaceutical sales statistics MAT6/2016 (7/2015–6/2016)

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy.

Total sales of all Parkinson’s drugs containing entacapone:

EUR or USD million

 

MAT6/2016

MAT6/2015

Change %

United States

USD

71

96

-26%

Europe TOP 5

EUR

118

135

-12%

Japan

EUR

72

60

+21%

Source: IMS Health pharmaceutical sales statistics MAT6/2016 (7/2015–6/2016)

 

Total sales of Orion’s branded Parkinson’s drugs:

EUR or USD million

 

MAT6/2016

MAT6/2015

Change %

United States*

USD

9

14

-34%

Europe TOP 5

EUR

80

108

-25%

Japan

EUR

72

60

+21%

Source: IMS Health pharmaceutical sales statistics MAT6/2016 (7/2015–6/2016)

*) Sales of generic entacapone products by Sandoz, which is part of the Novartis Group, were previously included in US sales but are no longer included.

Sales of Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan mainly because Stalevo was launched in that market during 2015. The market share of Orion’s branded Parkinson’s drugs was 1% in the United States, on average 9% in the five largest European markets and 12% in Japan.

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in June 2016 were up by 4% at EUR 530 (511) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 26% at EUR 41 (32) million in Europe.

 

Published on 19 July 2016

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–June 2016 was up by 3% on the previous year at EUR 1,106 (1,071) million. Orion was able to increase its sales faster than market growth, and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–June 2016 amounted to EUR 143 (129) million, up by 11% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 13% (12%).

 

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for under 15% of the Group’s net sales.

 

Total sales of all Parkinson’s drugs:

EUR or USD million

 

MAT3/2016

MAT3/2015

Change %

United States

USD

883

833

+6%

Europe TOP 5

EUR

921

974

-5%

Japan

EUR

584

521

+12%

Source: IMS Health pharmaceutical sales statistics MAT3/2016 (4/2015–3/2016)

 

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy.

 

Total sales of all Parkinson’s drugs containing entacapone:

EUR or USD million

 

MAT3/2016

MAT3/2015

Change %

United States

USD

78

102

-23%

Europe TOP 5

EUR

122

140

-13%

Japan

EUR

68

55

+23%

Source: IMS Health pharmaceutical sales statistics MAT3/2016 (4/2015–3/2016)

 

Total sales of Orion’s branded Parkinson’s drugs:

EUR or USD million

 

MAT3/2016

MAT3/2015

Change %

United States

USD

17

17

+4%

Europe TOP 5

EUR

87

117

-26%

Japan

EUR

68

55

+23%

Source: IMS Health pharmaceutical sales statistics MAT3/2016 (4/2015–3/2016)

 

Salesof Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan mainly because Stalevo was launched in that market during 2015. The market share of Orion’s branded Parkinson’s drugs was 2% in the United States, on average 9% in the five largest European markets and 12% in Japan.

 

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in March 2016 were up by 4% at EUR 527 (507) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 27% at EUR 38 (30) million in Europe.

Published on 27 April 2016

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–March 2016 was up by 2% on the previous year at EUR 534 (521) million. Orion was able to increase its sales faster than market growth, and strengthened its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–March 2016 amounted to EUR 69 (63) million, up by 11% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 13% (12%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for under 15% of the Group’s net sales.

 

Total sales of all Parkinson’s drugs:

EUR or USD million

 

2015

2014

Change %

United States

USD

846

812

+4%

Europe TOP 5

EUR

929

992

-6%

Japan

EUR

573

507

+13%

Source: IMS Health pharmaceutical sales statistics MAT12/2015 (1/2015–12/2015)

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy.

 

Total sales of all Parkinson’s drugs containing entacapone:

EUR or USD million

 

2015

2014

Change %

United States

USD

83

108

-23%

Europe TOP 5

EUR

126

144

-13%

Japan

EUR

66

54

+23%

Source: IMS Health pharmaceutical sales statistics MAT12/2015 (1/2015–12/2015)

 

Total sales of Orion’s branded Parkinson’s drugs:

EUR or USD million

 

2015

2014

Change %

United States

USD

17

17

+2%

Europe TOP 5

EUR

95

123

-23%

Japan

EUR

66

54

+23%

Source: IMS Health pharmaceutical sales statistics MAT12/2015 (1/2015–12/2015)

Salesof Orion’s branded Parkinson’s drugs decreased in Europe due to commencement of generic competition. Sales increased in Japan mainly because Stalevo was launched in that market during 2015. The market share of Orion’s branded Parkinson’s drugs was 2% in the United States, on average 10% in the five largest European markets and 12% in Japan.

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in December 2015 were up by 5% at EUR 525 (501) million. According to IMS Health pharmaceutical sales statistics, sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 30% at EUR 36 (28) million in Europe.